Skip to main content

Table 1 Patient Demographics and Clinical Characteristics

From: Cytoreductive treatment patterns among US veterans with polycythemia vera

  Patients With PV (N = 7718)
Age at index date,a y
 Mean (SD) 65.9 (11.3)
 Median (range) 64 (21–93)
Age, n (%)
 18–45 y 256 (3.3)
 46–59 y 2004 (26.0)
  ≥ 60 y 5458 (70.7)
Sex, n (%)
 Male 7557 (97.9)
Race/ethnicity, n (%)
 White 4932 (63.9)
 Black 404 (5.2)
 Hispanic 275 (3.6)
 Otherb 134 (1.7)
 Unavailablec 1973 (25.6)
Comorbid conditions, pre-indexa
 Deyo-Charlson Comorbidity Index, mean (SD) 1.4 (1.7)
 Chronic Disease Score, mean (SD) 6.3 (4.2)
 Most frequent comorbidities, n (%)  
  Hypertension 5531 (71.7)
  Dyslipidemia 4181 (54.2)
  Diabetes 1851 (24.0)
  Bleedingd 669 (8.7)
   Major 512 (6.6)
   Minor 262 (3.4)
History of smoking,e n (%) 2551 (33.1)
Elevated, pre-index,a n/Nf (%)
 Hematocrit level 5608/6214 (90.2)
 WBC count 2365/6477 (36.5)
Thrombotic events,d pre-index,a n (%)
 Arterial thrombosis 681 (8.8)
 Venous thrombosis 349 (4.5)
Cardiovascular events pre-index,a n (%) 1315 (17.0)
  1. ICD-9-CM International Classification of Diseases, Ninth Edition, Clinical Modification, PV polycythemia vera, WBC white blood cell
  2. aThe index date was defined as the date of each respective patient’s first claim with a PV diagnosis during the identification period
  3. bHawaiian or other Pacific Islander (0.8%), Alaska native or American Indian (0.6%), Asian (0.4%)
  4. cMissing (21.1%), declined to answer (3.1%), or unknown by patient (1.4%)
  5. dNumber of patients with ≥1 event. Patients may be counted in > 1 subcategory
  6. eSmoking status was determined through ICD-9-CM code 305.1, V15.82
  7. fElevated defined as hematocrit level ≥ 45%, WBC count ≥11 × 109/L; N represents patients with evaluable laboratory data